Boston An independent LDT provider
Immunovia

Advancing early detection of pancreatic cancer

Immunovia is focused on revolutionizing blood based diagnosis and improving survival rates for the patients with complex diseases.

Immunovia, Inc.

IMMray™ PanCan-d now exclusively available from Immunovia, Inc.

IMMray™ PanCan-d is the first blood-based test dedicated to early detection of pancreatic cancer. It is exclusively available as a laboratory developed test (LDT) from Immunovia, Inc., Marlborough, USA.

About us

About Immunovia

Immunovia is a diagnostic company developing and commercializing highly accurate blood tests based on IMMray™, Immunovia’s proprietary platform which provides antibody biomarker microarray analysis for early detection of cancer and autoimmune diseases.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see www.immunoviainc.com. European launch plan will be communicated during the second half of 2021.

Immunovia has initiated since 2016 a prospective clinical validation program for high risk groups for pancreatic cancer involving 30 hospitals and over 10,000 patients from USA and Europe.

Read more about Immunovia

Decorative image
Presentation

Immunovia Q2 2021 Presentation

Immunovia Q2 Report 2021 presentation from August 19th, 2021 with CEO Patrik Dahlen; Medical Director Dr. Thomas King and Sr. Marketing Director US Cindy Callahan

View presentation